Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

BI adds to cancer pipeline with CureVac’s mRNA vaccine CV9202

Executive Summary

CureVac GMBH (oncology and infectious disease mRNA therapeutics) licensed Boehringer Ingelheim GMBH exclusive worldwide rights to its Phase I mRNA vaccine CV9202 for lung cancer.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register